

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

CONNEQT Health Limited

ABN

81 113 252 234

Quarter ended ("current quarter")

30 September 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	1,301	1,301
1.2 Payments for		
(a) research and development	(98)	(98)
(b) product manufacturing and operating costs	(1,025)	(1,025)
(c) advertising and marketing	(521)	(521)
(d) leased assets	-	-
(e) staff costs	(2,003)	(2,003)
(f) administration and corporate costs	(460)	(460)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(251)	(251)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other	-	-
1.9 Net cash from / (used in) operating activities	(3,057)	(3,057)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(4)	(4)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other	-	-
2.6	Net cash from / (used in) investing activities	(4)	(4)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	1,104	1,104
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(45)	(45)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (Repayment of lease liabilities)	(60)	(60)
3.10	Net cash from / (used in) financing activities	999	999

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	2,566	2,566
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,057)	(3,057)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(4)	(4)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	999	999
4.5	Effect of movement in exchange rates on cash held	(3)	(3)
4.6	Cash and cash equivalents at end of period	501	501

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	501	2,566
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	501	2,566

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	343
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	1,476	1,476
7.2	Credit standby arrangements	-	-
7.3	Other	-	-
7.4	Total financing facilities	1,476	1,476
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	<p><i>A balance of US\$0.25m (A\$0.36m) remains of the US\$1.5m (A\$2.29m) Promissory Note (Announced 20 November 2023) with its US legal counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation (WSGR) relating to US legal fees from the Company's withdrawn NASDAQ IPO.</i></p> <p><i>During the June 2026 quarter, CONNEQT Health entered into an R&D Loan Facility with Kashcade RD1 Pty Ltd for \$1,115,000. The amount funded reflects the expected pro-rated FY2026 R&D Tax Incentive refund based on actual expenditure between 1 July 2025 and 31 March 2026. Key terms of the loan are:</i></p> <ul style="list-style-type: none"> <i>• Interest rate of 1.38% per month</i> <i>• Maturity date of 30 November 2026</i> <i>• Minimum interest period of 90 days</i> <i>• Repayment is secured by the FY2026 R&D Tax Incentive refund, which is expected to be received in the December 2026 quarter and will be applied to repay the facility.</i> 		
8.	Estimated cash available for future operating activities	\$A'000	
8.1	Net cash from / (used in) operating activities (item 1.9)	(3,057)	
8.2	Cash and cash equivalents at quarter end (item 4.6)	501	
8.3	Unused finance facilities available at quarter end (item 7.5)	-	
8.4	Total available funding (item 8.2 + item 8.3)	501	
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	0.16	
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:		
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?		
	<p>Answer:</p> <p>No. The Company expects net operating cash outflows to reduce in Q2, as it reduces Consumer advertising expenses in Q2/Q3 in preparation for the H2 launch of its SaMD and Pulse (generation 2) solutions, whilst still settling existing creditors and continuing to market the Consumer and Enterprise solutions. In addition, the receipt of the FY2026 R&D Tax Incentive refund in the December 2026 quarter and receipt of R&D loan funds relating to FY27 will positively affect the quarterly cash flows.</p>		

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

Yes. The Board is working on a comprehensive funding package comprising both debt and equity, including:

- A \$1.5m FY2026 R&D Tax Incentive refund is expected in the December 2026 quarter, which will be applied to repay the existing Kashcade R&D loan facility (\$1.1m);
- a new \$1.5m R&D loan facility to be secured against the FY2027 R&D Tax Incentive refund, subject to due diligence and definitive documentation;
- an inventory funding facility of up to \$1.5m to support Pulse inventory purchases, with a term sheet received subsequent to the quarter and progressing through due diligence and documentation; and
- an equity capital raising, expected to be undertaken in the December 2026 quarter.

The Company has a successful track record of raising both equity and debt financing, including \$9.9m in net financing cash flows during FY2026, and the Directors believe these steps are likely to be successful.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Yes. The Directors believe that if required, the Company has the ability to raise additional capital on a timely basis and has a proven capability of doing so.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 October 2026

Authorised by: The Board of Directors
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.